ATORX Stock Overview
A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.32 |
| 52 Week High | SEK 1.57 |
| 52 Week Low | SEK 0.34 |
| Beta | 1.38 |
| 11 Month Change | 18.04% |
| 3 Month Change | 44.17% |
| 1 Year Change | 226.02% |
| 33 Year Change | -76.77% |
| 5 Year Change | -90.98% |
| Change since IPO | -96.53% |
Recent News & Updates
Recent updates
Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?
Dec 01
We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate
Dec 21Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Jul 30Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Jan 06Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation
Aug 18Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation
Apr 11Shareholder Returns
| ATORX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.8% | -5.4% | -4.2% |
| 1Y | 226.0% | 18.1% | 12.5% |
Return vs Industry: ATORX exceeded the Swedish Biotechs industry which returned 21% over the past year.
Return vs Market: ATORX exceeded the Swedish Market which returned 17% over the past year.
Price Volatility
| ATORX volatility | |
|---|---|
| ATORX Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ATORX's share price has been volatile over the past 3 months.
Volatility Over Time: ATORX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 51 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| ATORX fundamental statistics | |
|---|---|
| Market cap | SEK 1.00b |
| Earnings (TTM) | -SEK 234.29m |
| Revenue (TTM) | SEK 45.95m |
21.8x
P/S Ratio-4.3x
P/E RatioIs ATORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATORX income statement (TTM) | |
|---|---|
| Revenue | SEK 45.95m |
| Cost of Revenue | SEK 188.24m |
| Gross Profit | -SEK 142.29m |
| Other Expenses | SEK 92.01m |
| Earnings | -SEK 234.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 24, 2024
| Earnings per share (EPS) | -0.31 |
| Gross Margin | -309.63% |
| Net Profit Margin | -509.86% |
| Debt/Equity Ratio | 0% |
How did ATORX perform over the long term?
See historical performance and comparison